ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0312

The Use of Electromyography as a Screening Tool in Sarcoidosis-associated Neuropathy

Kristen Caldwell1, Sindhuja Koppu1, Huzaefah Syed2, Aamer Syed1, Jordana Kron1, Thomas Iden1 and Kelly Gwathmey1, 1Virginia Commonwealth University, Richmond, VA, 2Virginia Commonwealth University Medical Center, Richmond, VA

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, neurology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Small fiber neuropathy (SFN) is the most common peripheral nervous system manifestation of sarcoidosis. Diagnosis of SFN includes clinical evaluation, occasionally skin biopsy to evaluate intraepidermal nerve fiber density, and electrodiagnostic studies. The utility of these tests to aid in diagnosis of sarcoidosis-associated SFN is unclear. This study evaluates the yield of normal electromyography (EMG) in diagnosing SFN.

Methods: This is a cross-sectional study comparing 19 patients with biopsy-confirmed sarcoidosis with and without normal EMG. Participants were evaluated for SFN according to the Toronto Consensus Criteria (TCC) with possible, probable, or definite SFN; the Utah Early Neuropathy Scale (UENS) that captures both small and large sensory fiber function; physician impression of neuropathy (PIN); and skin biopsy.

Results: In total, 19 patients with age ranging 30-70 years were recruited, including thirteen participants with normal EMG and 6 participants with abnormal EMG. Of this cohort, 66.7% of participants with abnormal EMG had PIN compared to 61.5% of those with normal EMG (p=1.00). Those with normal EMG had a lower mean UENS score (M=5.69, SD=4.50) compared to those with abnormal EMG (M=7.83, SD=5.49, p=0.43). When evaluated by TCC, 46.2% with normal EMG tested positive for SFN compared to 66.7% of those with abnormal EMG (p =0.63). In addition, 15.4% with normal EMG had positive biopsy suggesting pure SFN compared to 33.3% (p=0.59).

Conclusion: Though this study aimed to correlate normal EMG data with clinically suspected SFN, surprisingly 4 of 12 participants with clinically suspected SFN had abnormal EMG and 2 of 7 participants without suspected SFN had incidental EMG abnormalities. Notably, those with alternative causes of neuropathy (e.g., diabetes) were excluded. Participants with an abnormal EMG were more likely to have a higher UENS score, consistent with impaired large fiber function. Skin biopsy suggesting small fiber dysfunction was present in some patients with normal EMG (likely pure small fiber neuropathy) and some with abnormal EMG (likely mixed neuropathy). Although these findings were not statistically significant, there are clinically significant correlates. Despite a small sample size, our findings suggest that EMG studies may not be an adequate screening instrument for sarcoidosis-associated polyneuropathy.

Supporting image 1

Table 1. Biopsy-confirmed sarcoidosis patients, with normal and abnormal EMG, were evaluated for small fiber neuropathy utilizing various screening tools and histologic testing.

Supporting image 2

Figure 1. Mean total score of Utah Early Neuropathy Scale for participants with biopsy-confirmed sarcoidosis, comparing those with normal EMG and abnormal EMG.

Supporting image 3

Figure 2. Comparison of Participants with Abnormal and Normal Electromyogram. Graphs depict percentage of participants with abnormal skin biopsy suggestive of small fiber neuropathy, positive for small fiber neuropathy according to Toronto Consensus Criteria, and clinical impression of neuropathy by physician assessment.


Disclosures: K. Caldwell: None; S. Koppu: None; H. Syed: None; A. Syed: None; J. Kron: None; T. Iden: None; K. Gwathmey: None.

To cite this abstract in AMA style:

Caldwell K, Koppu S, Syed H, Syed A, Kron J, Iden T, Gwathmey K. The Use of Electromyography as a Screening Tool in Sarcoidosis-associated Neuropathy [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-use-of-electromyography-as-a-screening-tool-in-sarcoidosis-associated-neuropathy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-use-of-electromyography-as-a-screening-tool-in-sarcoidosis-associated-neuropathy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology